美国最高法院审查米非司酮可及性案件，对 FDA 的安全评估提出异议。 US Supreme Court to review mifepristone accessibility case, disputing FDA's safety assessment.
美国最高法院将审查一个可能影响米非司酮可及性的案件，米非司酮是美国最常见的堕胎类型中使用的药物。 The US Supreme Court is set to review a case that could impact the accessibility of mifepristone, a drug used in the most common type of abortion in the US. 核心争议是，FDA 在让米非司酮更容易获得（包括通过邮购药店）时是否忽视了严重的安全问题。 The central dispute is whether the FDA overlooked serious safety issues when they made mifepristone more accessible, including through mail-order pharmacies. 医疗专业人士声称米非司酮是 FDA 批准的“最安全的药物之一”，而一个基督教保守派团体起诉该机构，将数以万计的紧急并发症归因于该药物。 Medical professionals claim mifepristone is "among the safest medications" approved by the FDA, while a Christian conservative group suing the agency attributes tens of thousands of emergency complications to the drug.